Literature DB >> 16501087

Replication and clearance of Venezuelan equine encephalitis virus from the brains of animals vaccinated with chimeric SIN/VEE viruses.

Slobodan Paessler1, Haolin Ni, Olga Petrakova, Rafik Z Fayzulin, Nadezhda Yun, Michael Anishchenko, Scott C Weaver, Ilya Frolov.   

Abstract

Venezuelan equine encephalitis virus (VEEV) is an important, naturally emerging zoonotic pathogen. Recent outbreaks in Venezuela and Colombia in 1995, involving an estimated 100,000 human cases, indicate that VEEV still poses a serious public health threat. To develop a safe, efficient vaccine that protects against disease resulting from VEEV infection, we generated chimeric Sindbis (SIN) viruses expressing structural proteins of different strains of VEEV and analyzed their replication in vitro and in vivo, as well as the characteristics of the induced immune responses. None of the chimeric SIN/VEE viruses caused any detectable disease in adult mice after either intracerebral (i.c.) or subcutaneous (s.c.) inoculation, and all chimeras were more attenuated than the vaccine strain, VEEV TC83, in 6-day-old mice after i.c. infection. All vaccinated mice were protected against lethal encephalitis following i.c., s.c., or intranasal (i.n.) challenge with the virulent VEEV ZPC738 strain (ZPC738). In spite of the absence of clinical encephalitis in vaccinated mice challenged with ZPC738 via i.n. or i.c. route, we regularly detected high levels of infectious challenge virus in the central nervous system (CNS). However, infectious virus was undetectable in the brains of all immunized animals at 28 days after challenge. Hamsters vaccinated with chimeric SIN/VEE viruses were also protected against s.c. challenge with ZPC738. Taken together, our findings suggest that these chimeric SIN/VEE viruses are safe and efficacious in adult mice and hamsters and are potentially useful as VEEV vaccines. In addition, immunized animals provide a useful model for studying the mechanisms of the anti-VEEV neuroinflammatory response, leading to the reduction of viral titers in the CNS and survival of animals.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16501087      PMCID: PMC1395430          DOI: 10.1128/JVI.80.6.2784-2796.2006

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  51 in total

1.  Improved mucosal protection against Venezuelan equine encephalitis virus is induced by the molecularly defined, live-attenuated V3526 vaccine candidate.

Authors:  M K Hart; K Caswell-Stephan; R Bakken; R Tammariello; W Pratt; N Davis; R E Johnston; J Smith; K Steele
Journal:  Vaccine       Date:  2000-07-01       Impact factor: 3.641

2.  Comparative neurovirulence of attenuated and non-attenuated strains of Venezuelan equine encephalitis virus in mice.

Authors:  G V Ludwig; M J Turell; P Vogel; J P Kondig; W K Kell; J F Smith; W D Pratt
Journal:  Am J Trop Med Hyg       Date:  2001 Jan-Feb       Impact factor: 2.345

3.  Differences between C57BL/6 and BALB/cBy mice in mortality and virus replication after intranasal infection with neuroadapted Sindbis virus.

Authors:  D C Thach; T Kimura; D E Griffin
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

4.  Contribution of T cells to mortality in neurovirulent Sindbis virus encephalomyelitis.

Authors:  Jennifer F Rowell; Diane E Griffin
Journal:  J Neuroimmunol       Date:  2002-06       Impact factor: 3.478

Review 5.  Genetic determinants of Venezuelan equine encephalitis emergence.

Authors:  S C Weaver; M Anishchenko; R Bowen; A C Brault; J G Estrada-Franco; Z Fernandez; I Greene; D Ortiz; S Paessler; A M Powers
Journal:  Arch Virol Suppl       Date:  2004

6.  Recombinant sindbis/Venezuelan equine encephalitis virus is highly attenuated and immunogenic.

Authors:  Slobodan Paessler; Rafik Z Fayzulin; Michael Anishchenko; Ivorlyne P Greene; Scott C Weaver; Ilya Frolov
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

7.  Lymphocyte homing in xenotransplanted human thyroid tissue can be inhibited by LFA-1 and ICAM-1 antibodies.

Authors:  K Jungheim; G Caspar; K H Usadel; P M Schumm-Draeger
Journal:  Thyroid       Date:  2004-01       Impact factor: 6.568

8.  Generation and characterization of closely related epizootic and enzootic infectious cDNA clones for studying interferon sensitivity and emergence mechanisms of Venezuelan equine encephalitis virus.

Authors:  Michael Anishchenko; Slobodan Paessler; Ivorlyne P Greene; Patricia V Aguilar; Anne-Sophie Carrara; Scott C Weaver
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

9.  Genetically engineered, live attenuated vaccines for Venezuelan equine encephalitis: testing in animal models.

Authors:  William D Pratt; Nancy L Davis; Robert E Johnston; Jonathan F Smith
Journal:  Vaccine       Date:  2003-09-08       Impact factor: 3.641

10.  Characterization of lymphocyte subsets in the bronchiolar lymph nodes of BALB/c mice infected with cilia-associated respiratory bacillus.

Authors:  Lon V Kendall; Lela K Riley; Reuel R Hook; Cynthia L Besch-Williford; Craig L Franklin
Journal:  Comp Med       Date:  2002-08       Impact factor: 0.982

View more
  34 in total

1.  Stability of RNA virus attenuation approaches.

Authors:  Joan L Kenney; Sara M Volk; Jyotsna Pandya; Eryu Wang; Xiaodong Liang; Scott C Weaver
Journal:  Vaccine       Date:  2011-02-01       Impact factor: 3.641

2.  Chimeric Sindbis/eastern equine encephalitis vaccine candidates are highly attenuated and immunogenic in mice.

Authors:  Eryu Wang; Olga Petrakova; A Paige Adams; Patricia V Aguilar; Wenli Kang; Slobodan Paessler; Sara M Volk; Ilya Frolov; Scott C Weaver
Journal:  Vaccine       Date:  2007-08-15       Impact factor: 3.641

3.  Combined alphavirus replicon particle vaccine induces durable and cross-protective immune responses against equine encephalitis viruses.

Authors:  Douglas S Reed; Pamela J Glass; Russell R Bakken; James F Barth; Cathleen M Lind; Luis da Silva; Mary Kate Hart; Jonathan Rayner; Kim Alterson; Max Custer; Jeanne Dudek; Gary Owens; Kurt I Kamrud; Michael D Parker; Jonathan Smith
Journal:  J Virol       Date:  2014-08-13       Impact factor: 5.103

Review 4.  Encephalitic alphaviruses.

Authors:  Michele A Zacks; Slobodan Paessler
Journal:  Vet Microbiol       Date:  2009-08-28       Impact factor: 3.293

5.  CD4+ T cells provide protection against acute lethal encephalitis caused by Venezuelan equine encephalitis virus.

Authors:  Nadezhda E Yun; Bi-Hung Peng; Andrea S Bertke; Viktoriya Borisevich; Jennifer K Smith; Jeanon N Smith; Allison L Poussard; Milagros Salazar; Barbara M Judy; Michele A Zacks; D Mark Estes; Slobodan Paessler
Journal:  Vaccine       Date:  2009-05-03       Impact factor: 3.641

6.  Chimeric alphavirus vaccine candidates protect mice from intranasal challenge with western equine encephalitis virus.

Authors:  Svetlana Atasheva; Eryu Wang; A Paige Adams; Kenneth S Plante; Sai Ni; Katherine Taylor; Mary E Miller; Ilya Frolov; Scott C Weaver
Journal:  Vaccine       Date:  2009-05-27       Impact factor: 3.641

7.  γδ T Cells Play a Protective Role in Chikungunya Virus-Induced Disease.

Authors:  Kristin M Long; Martin T Ferris; Alan C Whitmore; Stephanie A Montgomery; Lance R Thurlow; Charles E McGee; Carlos A Rodriguez; Jean K Lim; Mark T Heise
Journal:  J Virol       Date:  2015-10-21       Impact factor: 5.103

Review 8.  Vaccines for Venezuelan equine encephalitis.

Authors:  Slobodan Paessler; Scott C Weaver
Journal:  Vaccine       Date:  2009-11-05       Impact factor: 3.641

9.  Chimeric alphavirus vaccine candidates for chikungunya.

Authors:  Eryu Wang; Eugenia Volkova; A Paige Adams; Naomi Forrester; Shu-Yuan Xiao; Ilya Frolov; Scott C Weaver
Journal:  Vaccine       Date:  2008-08-08       Impact factor: 3.641

10.  Improved efficacy of a gene optimised adenovirus-based vaccine for venezuelan equine encephalitis virus.

Authors:  Amanda J Williams; Lyn M O'Brien; Robert J Phillpotts; Stuart D Perkins
Journal:  Virol J       Date:  2009-07-31       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.